These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24292501)

  • 1. Bispecific Her2 × cotinine antibody in combination with cotinine-(histidine)2-iodine for the pre-targeting of Her2-positive breast cancer xenografts.
    Yoon S; Kim YH; Kang SH; Kim SK; Lee HK; Kim H; Chung J; Kim IH
    J Cancer Res Clin Oncol; 2014 Feb; 140(2):227-33. PubMed ID: 24292501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma.
    Cheal SM; Xu H; Guo HF; Patel M; Punzalan B; Fung EK; Lee SG; Bell M; Singh M; Jungbluth AA; Zanzonico PB; Piersigilli A; Larson SM; Cheung NV
    Theranostics; 2018; 8(18):5106-5125. PubMed ID: 30429889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of hapten-specific scFv from a phage display library and applications for HER2-positive tumor imaging.
    Kim HY; Wang X; Wahlberg B; Edwards WB
    Bioconjug Chem; 2014 Jul; 25(7):1311-22. PubMed ID: 24898150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis.
    McCall AM; Adams GP; Amoroso AR; Nielsen UB; Zhang L; Horak E; Simmons H; Schier R; Marks JD; Weiner LM
    Mol Immunol; 1999 May; 36(7):433-45. PubMed ID: 10449096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of bispecific antibody against antigen and hapten for immunodetection and immunopurification.
    Kim H; Park S; Lee HK; Chung J
    Exp Mol Med; 2013 Sep; 45(9):e43. PubMed ID: 24071736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK.
    Vaidyanathan G; Jestin E; Olafsen T; Wu AM; Zalutsky MR
    Nucl Med Biol; 2009 Aug; 36(6):671-80. PubMed ID: 19647173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates.
    Cheal SM; Xu H; Guo HF; Lee SG; Punzalan B; Chalasani S; Fung EK; Jungbluth A; Zanzonico PB; Carrasquillo JA; O'Donoghue J; Smith-Jones PM; Wittrup KD; Cheung NV; Larson SM
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):925-937. PubMed ID: 26596724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orientation and density control of bispecific anti-HER2 antibody on functionalized carbon nanotubes for amplifying effective binding reactivity to cancer cells.
    Kim HI; Hwang D; Jeon SJ; Lee S; Park JH; Yim D; Yang JK; Kang H; Choo J; Lee YS; Chung J; Kim JH
    Nanoscale; 2015 Apr; 7(14):6363-73. PubMed ID: 25785370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity and toxicity of anti-HER2 immunoRNase scFv 4D5-dibarnase in mice bearing human breast cancer xenografts.
    Balandin TG; Edelweiss E; Andronova NV; Treshalina EM; Sapozhnikov AM; Deyev SM
    Invest New Drugs; 2011 Feb; 29(1):22-32. PubMed ID: 19789841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates.
    Razumienko EJ; Scollard DA; Reilly RM
    J Nucl Med; 2012 Dec; 53(12):1943-50. PubMed ID: 23096164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanocell targeting using engineered bispecific antibodies.
    Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
    MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Construction and identification of anti-HER2 phage display single chain fragment of variable region library in human breast cancer].
    Lu XH; Wang ZW; Cai Y; Huang J; Zhu LH; Yang QL; Chen CJ
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 43(4):434-40. PubMed ID: 25187458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-HER2 scFv Expression in Escherichia coli SHuffle
    Ahmadzadeh M; Farshdari F; Nematollahi L; Behdani M; Mohit E
    Mol Biotechnol; 2020 Jan; 62(1):18-30. PubMed ID: 31691197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vivo HER2-Targeted Magnetic Resonance Tumor Imaging Using Iron Oxide Nanoparticles Conjugated with Anti-HER2 Fragment Antibody.
    Ding N; Sano K; Kanazaki K; Ohashi M; Deguchi J; Kanada Y; Ono M; Saji H
    Mol Imaging Biol; 2016 Dec; 18(6):870-876. PubMed ID: 27351762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced Tumor Volume and Increased Necrosis of Human Breast Tumor Xenograft in Mice Pretreated by a Cocktail of Three Specific Anti-HER2 scFvs.
    Nejatollahi F; Nadimi E; Noorafshan A; Moazen S; Alizadeh AM; Khalighfard S; Sahebkar A
    Curr Protein Pept Sci; 2024; 25(5):409-418. PubMed ID: 38018211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retargeting T cells for HER2-positive tumor killing by a bispecific Fv-Fc antibody.
    Wang L; He Y; Zhang G; Ma J; Liu C; He W; Wang W; Han H; Boruah BM; Gao B
    PLoS One; 2013; 8(9):e75589. PubMed ID: 24086580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific anti-HER2 and CD16 single-chain antibody production prolongs the use of stem cell-like cell transplantation against HER2-overexpressing cancer.
    Kasuya K; Shimazu M; Suzuki M; Itoi T; Aoki T; Tsuchida A
    Int J Mol Med; 2010 Feb; 25(2):209-15. PubMed ID: 20043129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A bispecific transmembrane antibody simultaneously targeting intra- and extracellular epitopes of the epidermal growth factor receptor inhibits receptor activation and tumor cell growth.
    Müller N; Hartmann C; Genssler S; Koch J; Kinner A; Grez M; Wels WS
    Int J Cancer; 2014 Jun; 134(11):2547-59. PubMed ID: 24243620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. scFv antibody: principles and clinical application.
    Ahmad ZA; Yeap SK; Ali AM; Ho WY; Alitheen NB; Hamid M
    Clin Dev Immunol; 2012; 2012():980250. PubMed ID: 22474489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Targeted detecting HER2 expression with recombinant anti HER2 ScFv-GFP fusion antibody].
    Gao G; Chen C; Yang Y; Yang H; Wang J; Zheng Y; Huang Q; Hu X
    Sheng Wu Gong Cheng Xue Bao; 2012 Aug; 28(8):1002-14. PubMed ID: 23185900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.